ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis (RA) and treatment"

  • Abstract Number: 2653 • 2016 ACR/ARHP Annual Meeting

    Results of a Comprehensive Review of Pulmonary Function and Safety Data in a Phase IIb Clinical Program Testing Anti-GM-CSF Receptor Antagonist Mavrilimumab for Treatment of RA

    GR Burmester1, MA Michaels2, D Close3, A Godwood3, K Middleton3, P Miranda4, J Vencovský5, JM Kremer6, IB McInnes7, M Albulescu^3 and Michael Weinblatt8, 1Charité – University Medicine Berlin, Berlin, Germany, 2MedImmune, Gaithersburg, MD, 3MedImmune, Cambridge, United Kingdom, 4Centro De Estudios Reumatológicos, Santiago, Chile, 5Charles University, Prague, Czech Republic, 6The Albany Medical College, Albany, NY, 7University of Glasgow, Glasgow, United Kingdom, 8Brigham and Women’s Hospital, Boston, MA

    Background/Purpose: RA is associated with significant pulmonary comorbidity and declines in lung function over time; but longitudinal assessment of pulmonary abnormalities in the context of…
  • Abstract Number: 610 • 2016 ACR/ARHP Annual Meeting

    A Systematic Review and Meta-Analysis of Comparative Efficacy of Biologics in Treating Patients with Rheumatoid Arthritis: Assessment of Long-Term Radiographic Progression from Published Clinical Trials

    Erin Murray1, Yekaterina Butylkova1, Alexandra Ellis1, Martha Skup2, Jasmina Kalabic3 and Vishvas Garg4, 1Doctor Evidence, Santa Monica, CA, 2AbbVie Inc., North Chicago, IL, 3AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, 4AbbVie Inc, North Chicago, IL

    Background/Purpose: Previously, several studies have meta-analyzed clinical, functional or structural efficacy of biologics in treating rheumatoid arthritis (RA) patients. However, the comparative efficacy of biologics…
  • Abstract Number: 3094 • 2016 ACR/ARHP Annual Meeting

    Factors Associated with Initial or Subsequent Choice of Biologic Disease Modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis

    Yinzhu Jin1, Rishi J. Desai1, Jun Liu1, Nam-Kyong Choi1 and Seoyoung Kim2,3, 1Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, 2Division of Pharmacoepidemiology and Pharmocoeconomics, Brigham and Women's Hospital, Boston, MA, 3Brigham and Women’s Hospita and, Harvard Medical School,, Boston, MA

    Background/Purpose:  Treatment with disease-modifying antirheumatic drugs (DMARDs) is considered the standard of care for rheumatoid arthritis (RA). Over the past two decades, major advances have…
  • Abstract Number: 637 • 2016 ACR/ARHP Annual Meeting

    Biologic Initiation Patterns Among Rheumatoid Arthritis Patients in Moderate or High Disease Activity While Using Conventional Disease Modifying Anti-Rheumatic Drugs

    Natalie Boytsov1, George W. Reed2, Leslie R Harrold2,3, Xiang Zhang1, Carol L Gaich1, Cynthia J Larmore1, Ying Shan2, S Rebello4 and Andre B. Araujo1, 1Eli Lilly and Company, Indianapolis, IN, 2Corrona, LLC, Southborough, MA, 3UMass Medical School, Worcester, MA, 4Epidemiology, Corrona, Southborough, MA

      Background/Purpose: The purpose of this study was to describe biologic initiation patterns over a 1-year follow-up period in rheumatoid arthritis (RA) patients with moderate…
  • Abstract Number: 3212 • 2016 ACR/ARHP Annual Meeting

    Treat-to-Target in RA: Does Early Simplified Disease Activity Index (SDAI) Remission Lead to Better 5-Year Functional Outcomes Than SDAI Low Disease Activity?

    Vibeke Norvang, Elisabeth Lie, Inge C Olsen, Eirik K Kristianslund, Tore K Kvien and Till Uhlig, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway

    Background/Purpose: The management of rheumatoid arthritis (RA) has evolved considerably during the last couple of decades, with current recommended practice being a treat-to-target approach, involving…
  • Abstract Number: 1540 • 2016 ACR/ARHP Annual Meeting

    “I Am Always in Pain Somewhere”: Continuing Unmet Need in Rheumatoid Arthritis

    Peter C. Taylor1, Rieke Alten2, Juan Jesus Gomez-Reino3, Roberto Caporali4, Philippe Bertin5, Laura Grant6, Elaine Brohan6, Jane Wells6, Radu Vasilescu7 and Miriam Tarallo8, 1Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, 2Charité University Medicine, Berlin, Germany, 3Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain, 4Università di Pavia, Pavia, Italy, 5Rheumatology, CHU Dupuytren, Limoges, France, 6Adelphi Values, Bollington, United Kingdom, 7Medical Affairs, Pfizer, Brussels, Belgium, 8GHV, Pfizer, Rome, Italy

    Background/Purpose: Despite advances in the RA treatment, substantial humanistic and economic burdens remain. This study of patients with RA, with moderate to severe disease activity…
  • Abstract Number: 1616 • 2016 ACR/ARHP Annual Meeting

    Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor-α Monoclonal Antibody: Long-Term Safety and Efficacy for up to 158 Weeks of Treatment in Patients with Rheumatoid Arthritis

    GR Burmester1, IB McInnes2, JM Kremer3, P Miranda4, J Vencovský5, A Godwood6, M Albulescu6, D Close^6 and Michael Weinblatt7, 1Charité – University Medicine Berlin, Berlin, Germany, 2University of Glasgow, Glasgow, United Kingdom, 3The Albany Medical College, Albany, NY, 4Centro De Estudios Reumatológicos, Santiago, Chile, 5Charles University, Prague, Czech Republic, 6MedImmune, Cambridge, United Kingdom, 7Brigham and Women’s Hospital, Boston, MA

    Background/Purpose: Inhibition of GM–CSFR-α is a novel approach to treat RA. Mavrilimumab, an investigational human monoclonal antibody targeting GM–CSFR-α, has demonstrated efficacy and an acceptable…
  • Abstract Number: 429 • 2015 ACR/ARHP Annual Meeting

    Treatment Preferences of Patients with Early Rheumatoid Arthritis: A Discrete-Choice Experiment

    Glen S. Hazlewood1,2, Claire Bombardier3, George A. Tomlinson4, Carter Thorne5, VP Bykerk6, Andrew Thompson7, Diane Tin8 and Deborah Marshall9, 1Medicine, University of Calgary, Calgary, AB, Canada, 2Institute of Health, Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, 3Division of Rheumatology and Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada, 4Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, 5Southlake Regional Health Centre, Newmarket, ON, Canada, 6Rheumatology, Hospital for Special Surgery, New York, NY, 7Rheumatology, St Joseph's Hlth Ctr, London, ON, Canada, 8The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, 9University of Calgary, Calgary, AB, Canada

    Background/Purpose: Treatment choices in early rheumatoid arthritis need to balance benefits, risks, and other considerations such as dosing and monitoring. The objective of this study…
  • Abstract Number: 2269 • 2015 ACR/ARHP Annual Meeting

    Rheumatologists Consider Patient Preferences and Costs When Choosing Treatments for Rheumatoid Arthritis (RA) Patients. a Cross-European Discrete Choice Experiment

    Monika Hifinger1, Mickaël Hiligsmann2, Sofia Ramiro3, Verity Watson4, Johan L. Severens5, Bruno Fautrel6, Loreto Carmona7, Till Uhlig8, Ronald van Vollenhoven9, Peggy Jacques10, Jacqueline Detert11, Carlo Alberto Scirè12, Florian Berghea13, Márta Péntek14, Jose canas Silva15, Andrew Keat16 and Annelies Boonen17, 1Rheumatology, University of Maastricht, Maastricht, Netherlands, 2Department of Health Services Research, University of Maastricht, Maastricht, Netherlands, 3Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4Health Economics Research Unit, University of Aberdeen, Aberdeen, United Kingdom, 5Institute of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, Netherlands, 6Rheumatology, AP-HP Pitié-Salpêtrière Hospital / Pierre and Marie Curie University Paris 6 GRC-08 (EEMOIS), Paris, France, 7Instituto de Salud Musculoesqueletica, Madrid, Spain, 8Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 9Rheumatology Unit, The Karolinska Institute, Stockholm, Sweden, 10University Hospital Ghent, Ghent, Belgium, 11Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 12Italian Society for Rheumatology, Milan, Italy, 13Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania, 14Corvinus University of Budapest, Budapest, Hungary, 15Rheumatology Department, Hospital Garcia de Orta, E.P.E., Almada, Portugal, 16Northwick Park Hospital, Harrow, United Kingdom, 17Care and Public Health Research Institute, Maastricht University Medical Center, Maastricht, Netherlands

    Background/Purpose: Economic considerations and patient preferences are increasingly important when choosing treatments. It is not known to what extent rheumatologists across Europe account for these…
  • Abstract Number: 431 • 2015 ACR/ARHP Annual Meeting

    Treatment Target in a Disease Activity Score Steered Treatment Protocol in Early Arthritis Patients: Low Disease Activity or Remission

    Gülsah Akdemir1, Iris M. Markusse2, Johannes H.L.M. van Groenendael3, André J. Peeters4, Esmeralda T. Molenaar5, Pit J.S.M. Kerstens6, Willem F. Lems7, T. W. J. Huizinga1 and Cornelia F. Allaart1, 1Rheumatology, LUMC, Leiden, Netherlands, 2LUMC, Leiden, Netherlands, 3Rheumatology, Franciscus Hospital, Roosendaal, Netherlands, 4Rheumatology, RDGG, Delft, Netherlands, 5Rheumatology, Groene Hart Hospital, Gouda, Netherlands, 6Rheumatology, Reade, Amsterdam, Netherlands, 7Rheumatology, VU Medical Center, Amsterdam, Netherlands

    Background/Purpose: To compare physicians' opinion on and adherence to treatment study protocols targeted at either Disease Activity Score (DAS) ≤2.4 or <1.6. Methods: The BeSt…
  • Abstract Number: 2313 • 2015 ACR/ARHP Annual Meeting

    Responder Rates and Numbers Needed to Treat Based on Clinically Meaningful Improvements in Patient Reported Outcomes (PROs) Including Health-Related Quality of Life (HRQoL) after Sarilumab Treatment during a Phase III Randomized Controlled Trial (RCT)

    Vibeke Strand1, Regina Rendas-Baum2, George J. Joseph3, Chieh-I Chen4, Hubert van Hoogstraten5, T. W. J. Huizinga6 and Mark C. Genovese7, 1Biopharmaceutical Consultant, Portola Valley, CA, 2QualityMetric Inc, Lincoln, RI, 3Global Health Economics & Outcomes Research (HEOR), Sanofi, Bridgewater, NJ, 4Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 5Sanofi, Bridgewater, NJ, 6Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 7Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA

    Background/Purpose: Sarilumab is a human monoclonal antibody (mAb) directed against the soluble IL-6 receptor (sIL-6R), administered subcutaneously (SC) every 2 weeks (q2w).  In the phase…
  • Abstract Number: 447 • 2015 ACR/ARHP Annual Meeting

    Components of Treatment Delay in Rheumatoid Arthritis Differ According to Autoantibody Status

    Arthur G Pratt1, Ben Hargreaves2, Dennis W Lendrem2, Osman Aslam2 and John D Isaacs2, 1Institute of Cellular Medicine (Musculoskeletal Research Group), National Institute for Health Research Newcastle Biomedical Research Centre based at Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom, 2Institute of Cellular Medicine (Musculoskeletal Research Group), NIHR Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom

    Background/Purpose: Despite a proliferation of early arthritis (EA) clinics intended to expedite the diagnosis of rheumatoid arthritis (RA), patients continue to experience substantial and multifactorial…
  • Abstract Number: 2491 • 2015 ACR/ARHP Annual Meeting

    Documentation of Disease Activity Score As Part of a Treat to Target Strategy in Rheumatoid Arthritis

    Sarah Homann1 and Beth Scholz2, 1Rheumatology, University of Texas Health Sciences Center at Houston, Houston, TX, 2University of Texas Health Sciences Center at Houston, Houston, TX

    Background/Purpose: Compared to routine care, the Treat to Target (TTT) strategy for rheumatoid arthritis (RA) has been validated to improve functional and radiographic outcomes via…
  • Abstract Number: 458 • 2015 ACR/ARHP Annual Meeting

    First Year Canadian Experience with Subcutaneous Abatacept in Routine Practice for the Treatment of Patients with Rheumatoid Arthritis: Data from the Orencia Response Program (ORP) Network

    Boulos Haraoui1, Louis Coupal2, Radmila Day3, Lionel Budry4 and Youb Chalabi5, 1Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, 2Rheumatology, Institut de recherche en rhumatologie de Montréal (IRRM), Montréal, QC, Canada, 3None, Montreal, QC, Canada, 4Bristol Myers Squibb Canada, St-Laurent, QC, Canada, 5Bristol Myers Squibb, Montreal, QC, Canada

    Background/Purpose: The subcutaneous (SC) formulation of abatacept (ABA) has been available in Canada since January 2014. Here we report first year experience with SC ABA…
  • Abstract Number: 2656 • 2015 ACR/ARHP Annual Meeting

    Analysis of Morning Stiffness Response in Rheumatoid Arthritis Patients with Low Disease Activity Receiving Delayed-Release Prednisone Plus Dmards As Compared to Placebo Plus Dmards

    Rieke Alten1, Robert J. Holt2, Jeffrey D. Kent3 and Frank Buttgereit4, 1Charité Univ Medicine, Berlin, Germany, 2College of Pharmacy, University of Illinois-Chicago, Vernon Hill, IL, 3Medical Affairs, Horizon Pharma, Inc, Deerfield, IL, 4Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany

    Background/Purpose: Patient reported outcomes such as morning stiffness are reported frequently in rheumatoid arthritis (RA) patients. But little has been reported about the presence and…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology